Abstract
Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this review we assess existing literature concerning real-world effectiveness of palbociclib. Survival outcomes in terms of progression-free survival and overall survival are discussed and compared among the included real-world studies and in relation to the phase III PALOMA trials.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | FSO |
| Tidsskrift | Future Science OA |
| Vol/bind | 10 |
| Udgave nummer | 1 |
| ISSN | 2056-5623 |
| DOI | |
| Status | Udgivet - 1 dec. 2024 |